|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours:a phase 1 dose-escalation trial 显示文摘 | Falchook GS Long GV Kurzrock R | 2012 | Lancet2012，379，9829： | 1 |
| 2 | BRAF inhibitor dab- rafenib in patients with metastatic BRAF-mutant thyroid cancer 显示文摘 | Falchook GS Millward M Hong D | 2015 | Thyroid2015，25，10： | 1 |
| 3 | Results of the first-in- human phase I trial assessing MSC2156119J (EMD 1214063) , an oral selective c-Met inhibitor, in patients (pts) with advanced solid tumors显示文摘 | Falchook GS Hang DS Amin HM | 2014 | J Clin Oneol2014，32，15： | 1 |
| 4 | Dabrafenib in patients with melanoma,untreated brain metastases,and other solid tumours:a phase 1 dose-escalation trial显示文摘 | Falchook GS Long GV Kurzrock R | | 0，，9829： | 1 |
| 5 | Relative bio- availability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors 显示文摘 | Falchook GS Venkatakrishnan K Sarantopoulos J et aI | 2015 | Int J Clin Pharmacol Ther2015，53，7： | 1 |
| 6 | Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer 显示文摘 | Falchook GS Naing A Hong DS | 2013 | Oncotarget2013，14，1： | 1 |
| 7 | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid turnouts: a phase 1 dose-escalation trial显示文摘 | Falchook GS Long GV Kurzrock R | 2012 | Lancet2012，379，9829： | 1 |
| 8 | Safety, pharmacokinetic, pharmacodynamie, and efficacy data for the o- ral MEK inhibitor trametinib: a phase 1 dose-escalation trial显示文摘 | INFANTE JR FECHER LA FALCHOOK GS | 2012 | Lancet Oncol2012，13，8： | 1 |
| 9 | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial 显示文摘 | Falchook GS Long GV Kurzrock R | 2012 | Lancet2012，379，9829： | 1 |
| 10 | Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer显示文摘 | Falchook GS Naing A Hong DS | 2013 | Oncotarget2013，4，1： | 1 |
| 11 | Dual HER2inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer显示文摘 | Falchook GS Moulder SL Wheler JJ | 2013 | Ann Oncol2013，24，12： | 1 |
| 12 | Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial 显示文摘 | Falchook GS Long GV Kurzrock R | 2012 | Lancet2012，379，9829： | 1 |
| 13 | Dual EGFR inhibition in combination with anti-VEGF treatment :A phase I clinical trial in non-small cell lung cancer显示文摘 | Falchook GS Naing A Hong DS | 2013 | Oncotarget2013，14，1： | 1 |
| 14 | Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer 显示文摘 | Falchook GS Moulder SL Wheler JJ | 2013 | Ann Oncol2013，24，12： | 1 |
| 15 | Dabrafenib in patients with melanoma,untreated brain metastases,and other solid tumours:a phase 1 dose-escalation trial显示文摘 | FALCHOOK GS LONG GV KURZROCK R | 2012 | Lancet2012，379，9829： | 1 |
| 16 | Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lurLg cancer显示文摘 | Falchook GS Naing A Hong DS | 2013 | Oncotarget2013，4，1： | 1 |
| 17 | BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib ( GSK2118436 ) and whole exomic sequencing for analysis of acquired resistance 显示文摘 | Falchook GS Trent JC Heinrich MC | 2013 | Oneotarget2013，4，2： | 1 |
| 18 | BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer 显示文摘 | Falchook GS Millward M Hong D | 2015 | Thyroid2015，25，1： | 1 |
| 19 | A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibltor,in patients with advanced solid tumors 显示文摘 | Hong DS Bowles DW Falchook GS | 2012 | Clin Cancer Res2012，18，15： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员